肝病谱系中肠道微生物组与功能特征随疾病分期变化:一项整合多队列研究
该研究分析1168份粪便样本(16S rRNA测序,其中141份行鸟枪法宏基因组测序),并整合2376份公开宏基因组数据(含734份肝病相关),采用机器学习多队列分析。结果显示微生物多样性随疾病严重程度下降、低丰富度肠型扩张;肝炎缺乏分类学标志但具有生物合成上调的功能特征,晚期阶段出现Ligilactobacillus和Veillonella等一致标志及口腔-肠道传播证据;口腔来源Veillonella spp和低丰富度肠型与死亡率增加显著相关。
要点
- 肝病进展伴随微生物多样性下降和低丰富度肠型扩张。
- 肝炎以功能标志(生物合成上调)为主,缺乏分类学标志。
- 口腔来源Veillonella spp和低丰富度肠型与死亡率增加相关。
核心结论
- 肝病谱系存在分期依赖的肠道微生物生态与功能重塑。
- 微生物标志物有望用于肝病无创诊断和预后风险分层。
研究设计与样本
- 分析1168例粪便样本(健康对照、脂肪肝、肝炎、肝硬化、肝细胞癌)行16S rRNA测序,其中141例行鸟枪法宏基因组测序。
- 整合2376份公开宏基因组数据集(含734份肝病相关)进行外部验证。
- 采用机器学习多队列分析识别微生物标志物、评估危险因素并分类疾病分期。
主要发现
- 微生物多样性随疾病严重程度下降,低丰富度肠型扩张。
- 肝炎缺乏分类学标志,但具有生物合成上调的保守功能特征。
- 晚期阶段出现Ligilactobacillus和Veillonella等一致标志,菌株水平证据证实口腔-肠道传播。
- 功能谱从肝炎的合成代谢前体合成,经肝硬化的毒力因子产生,至肝癌的腐败代谢。
- 口腔来源Veillonella spp扩张和低丰富度肠型与死亡率增加显著相关。
关键数值与推荐
- 微生物多样性下降和低丰富度肠型扩张与疾病严重程度相关。
- 肝炎的功能标志为生物合成上调。
- 晚期阶段标志包括Ligilactobacillus和Veillonella。
- 口腔来源Veillonella spp和低丰富度肠型与死亡率增加显著相关。
临床怎么用
- 可考虑将肠道微生物组标志物用于肝病无创诊断和预后风险分层。
- 关注低丰富度肠型和口腔来源Veillonella spp扩张以识别高死亡风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The gut-liver axis plays a critical role in liver disease progression; however, how gut microbial ecology and function vary across disease stages remains unclear. OBJECTIVE: To define stage-specific microbial and functional signatures and evaluate their diagnostic potential. DESIGN: We analysed faecal samples from 1168 individuals spanning healthy controls, fatty liver, hepatitis, cirrhosis and hepatocellular carcinoma by 16S rRNA sequencing, with a subset (n=141) profiled by shotgun metagenomics. To increase statistical power and enable external validation, 2376 publicly available metagenomic datasets, including 734 liver-related, were integrated. Machine learning-based multicohort analysis was used to identify microbial biomarkers, assess risk factors and classify disease stages. RESULTS: Microbial diversity declined and a low-richness enterotype expanded with disease severity. Machine learning revealed a discordance in hepatitis, which lacked taxonomic markers but was defined by a conserved functional signature of biosynthetic upregulation. In contrast, advanced stages featured consistent markers like Ligilactobacillus and Veillonella, with strain-level evidence confirming oral-gut transmission. Functional profiling delineated a metabolic continuum from anabolic precursor synthesis in hepatitis to virulence factor production in cirrhosis and putrefactive metabolism in carcinoma. Comparative analysis confirmed that these signatures were distinct from those in non-liver metabolic and oncologic disorders. Importantly, the expansion of oral-derived Veillonella spp and the low-richness enterotype were significantly associated with increased mortality. CONCLUSION: This large-scale study delineates stage-dependent ecological and functional remodelling of the gut microbiome across liver diseases. These findings highlight the potential of microbiome-based markers for non-invasive diagnosis and prognostic risk stratification in liver diseases.
引用
- Vázquez-Castellanos JF, Yoon SJ, Won SM, et al. Stage-dependent gut microbiome and functional signatures across the liver disease spectrum: an integrative multicohort study. Gut. 2026. PMID: 41871945. doi:10.1136/gutjnl-2025-337436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。